Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours von Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.

Volltext

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial von Motzer, Robert J, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Negrier, Sylvie, Prof, Oudard, Stephane, Prof, Gore, Martin E, Prof, Tarazi, Jamal, MD, Hariharan, Subramanian, MD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Rini, Brian I, MD

Volltext

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial von Hutson, Thomas E, Prof, Lesovoy, Vladimir, Prof, Al-Shukri, Salman, Prof, Stus, Viktor P, Prof, Lipatov, Oleg N, Prof, Bair, Angel H, PhD, Rosbrook, Brad, MS, Chen, Connie, PharmD, Kim, Sinil, MD, Vogelzang, Nicholas J, Prof

Volltext

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial von Rini, Brian I, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Kaprin, Andrey, Prof, Szczylik, Cezary, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Gorbunova, Vera A, Prof, Gore, Martin E, Prof, Rusakov, Igor G, Prof, Negrier, Sylvie, Prof, Ou, Yen-Chuan, Prof, Castellano, Daniel, MD, Lim, Ho Yeong, Prof, Uemura, Hirotsugu, Prof, Tarazi, Jamal, MD, Cella, David, PhD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Motzer, Robert J, MD

Volltext

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial von Rini, Brian I, Prof, Melichar, Bohuslav, Prof, Ueda, Takeshi, Prof, Grünwald, Viktor, MD, Fishman, Mayer N, Prof, Arranz, José A, MD, Bair, Angel H, PhD, Pithavala, Yazdi K, PhD, Andrews, Glen I, MS, Pavlov, Dmitri, PhD, Kim, Sinil, MD, Jonasch, Eric, MD

Volltext

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma von RINI, Brian I, WILDING, George, HUDES, Gary, STADLER, Walter M, KIM, Sinil, TARAZI, Jamal, ROSBROOK, Brad, TRASK, Peter C, WOOD, Laura, DUTCHER, Janice P

Volltext

The Cas9-gRNA ribonucleoprotein complex-mediated editing of pyrG in Ganoderma lucidum and unexpected insertion of contaminated DNA fragments von Eom, Hyerang, Choi, Yeon-Jae, Nandre, Rutuja, Han, Hui-Gang, Kim, Sinil, Kim, Minseek, Oh, Youn-Lee, Nakazawa, Takehito, Honda, Yoichi, Ro, Hyeon-Su

Volltext

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study von Kindler, Hedy L, Dr, Ioka, Tatsuya, MD, Richel, Dirk J, MD, Bennouna, Jaafar, MD, Létourneau, Richard, MD, Okusaka, Takuji, MD, Funakoshi, Akihiro, MD, Furuse, Junji, MD, Park, Young Suk, MD, Ohkawa, Shinichi, MD, Springett, Gregory M, MD, Wasan, Harpreet S, MB, Trask, Peter C, PhD, Bycott, Paul, PhD, Ricart, Alejandro D, MD, Kim, Sinil, MD, Van Cutsem, Eric, MD

Volltext

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study von COHEN, Ezra E. W, ROSEN, Lee S, TORTORICI, Michael, SHALINSKY, David R, LIAU, Katherine F, COHEN, Roger B, VOKES, Everett E, KIES, Merrill S, FORASTIERE, Arlene A, WARDEN, Francis P, KANE, Madeleine A, SHERMAN, Eric, KIM, Sinil, BYCOTT, Paul

Volltext

Heterokaryosis, the main obstacle in the generation of PPO1-edited Agaricus bisporus by CRISPR/Cas9 system von Choi, Yeon Jae, Eom, Hyerang, Yang, Seong-Hyeok, Nandre, Rutuja, Kim, Sinil, Kim, Minseek, Oh, Youn-Lee, Nakazawa, Takehito, Honda, Yoichi, Ro, Hyeon-Su

Volltext

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis von Rini, Brian I., Garrett, May, Poland, Bill, Dutcher, Janice P., Rixe, Olivier, Wilding, George, Stadler, Walter M., Pithavala, Yazdi K., Kim, Sinil, Tarazi, Jamal, Motzer, Robert J.

Volltext

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors von RINI, Brian I, SCHILLER, Joan H, KIM, Sinil, RIXE, Olivier, FRUEHAUF, John P, COHEN, Ezra E. W, TARAZI, Jamal C, ROSBROOK, Brad, BAIR, Angel H, RICART, Alejandro D, OLSZANSKI, Anthony J, LETRENT, Kristen J

Volltext

Comparative structural analysis on the mitochondrial DNAs from various strains of Lentinula edodes von Kim, Sinil, Eom, Hyerang, Nandre, Rutuja, Choi, Yeon Jae, Lee, Hwayong, Ryu, Hojin, Ro, Hyeon-Su

Volltext

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study von Rixe, Olivier, Prof, Bukowski, Ronald M, MD, Michaelson, M Dror, MD, Wilding, George, MD, Hudes, Gary R, MD, Bolte, Oliver, MD, Motzer, Robert J, MD, Bycott, Paul, DrPH, Liau, Katherine F, BS, Freddo, James, MD, Trask, Peter C, PhD, Kim, Sinil, MD, Rini, Brian I, MD

Volltext

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study von SCHILLER, Joan H, LARSON, Timothy, VON PAWEL, Joachim, IGNATIUS OU, S.-H, LIMENTANI, Steven, SANDLER, Alan, VOKES, Everett, KIM, Sinil, LIAU, Katherine, BYCOTT, Paul, OLSZANSKI, Anthony J

Volltext

Molecular analysis of B mating type diversity in Lentinula edodes von Ha, Byeongsuk, Moon, Yoon Jung, Song, Yelin, Kim, Sinil, Kim, Minseek, Yoon, Cheol-Won, Ro, Hyeon-Su

Volltext

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study von Spano, Jean-Philippe, Prof, Chodkiewicz, Catherine, MD, Maurel, Joan, MD, Wong, Ralph, MD, Wasan, Harpreet, MD, Barone, Carlo, Prof, Létourneau, Richard, MD, Bajetta, Emilio, MD, Pithavala, Yazdi, PhD, Bycott, Paul, DrPh, Trask, Peter, PhD, Liau, Katherine, BS, Ricart, Alejandro D, MD, Kim, Sinil, MD, Rixe, Olivier, Prof

Volltext

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer von RUGO, Hope S, STOPECK, Alison T, BAIR, Angel H, SOULIERES, Denis, JOY, Anil A, CHAN, Stephen, VERMA, Shailendra, LLUCH, Anna, LIAU, Katherine F, KIM, Sinil, BYCOTT, Paul, ROSBROOK, Brad

Volltext

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial von Ueda, Takeshi, Uemura, Hirotsugu, Tomita, Yoshihiko, Tsukamoto, Taiji, Kanayama, Hiroomi, Shinohara, Nobuo, Tarazi, Jamal, Chen, Connie, Kim, Sinil, Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki

Volltext

Mitochondrial Effects on the Physiological Characteristics of Lentinula edodes von Kim, Minseek, Yang, Seong-Hyeok, Han, Hui-Gang, Kim, Eunbi, Kim, Sinil, Oh, Youn-Lee, Ro, Hyeon-Su

Volltext